Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery (Q28274686)

27 March 2017

0 references

1 reference

Adem Y Dawed

3

0 references

Helle Krogh Pedersen

object named as

Helle Krogh Pedersen

2

0 references

author name string

Kaixin Zhou

1

1 reference

27 March 2017

Ewan R Pearson

4

0 references

Adem Y. Dawed

3

1 reference

27 March 2017

Ewan R. Pearson

4

1 reference

27 March 2017

language of work or name

English

0 references

publication date

June 2016

0 references

11 April 2016

1 reference

Nature Reviews Endocrinology

27 March 2017

published in

1 reference

Five years of GWAS discovery

27 March 2017

volume

12

0 references

issue

6

0 references

page(s)

337-46

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pharmacogenomics of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Insights from genome-wide association studies of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Type 2 diabetes: principles of pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Loss-of-function mutations in SLC30A8 protect against type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Recent advances in understanding the genetic architecture of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

SGLT inhibitors in management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genetic cause of hyperglycaemia and response to treatment in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pharmacogenetics goes genomic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Sequencing studies in human genetics: design and interpretation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genome partitioning of genetic variation for complex traits using common SNPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Statistical power to detect genetic (co)variance of complex traits using SNP data in unrelated samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Common SNPs explain a large proportion of the heritability for human height

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Metformin and the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genetic influences on the insulin response of the beta cell to different secretagogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Novel biological insights emerging from genetic studies of type 2 diabetes and related metabolic traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pharmacogenomics in clinical practice and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Exploiting complexity and the robustness of network architecture for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pharmacogenetics of oral antidiabetic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pharmacogenetics and personalized treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

An update on the pharmacogenomics of metformin: progress, problems and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Clinical Pharmacokinetics of Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

RS11212617 is associated with metformin treatment response in type 2 diabetes in Shanghai local Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Safety of antidiabetes medications: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Clinical development success rates for investigational drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

The support of human genetic evidence for approved drug indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Validating therapeutic targets through human genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Discovery and refinement of loci associated with lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Clinical risk factors, DNA variants, and the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

The Na(+)/glucose cotransporters: from genes to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Weight management in type 2 diabetes: current and emerging approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genotype to phenotype via network analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Cluster based prediction of PDZ-peptide interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Differential network biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Understanding multicellular function and disease with human tissue-specific networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Tissue specificity and the human protein interaction network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Enhancing the prioritization of disease-causing genes through tissue specific protein interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

A new initiative on precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

UK gears up to decode 100,000 genomes from NHS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Insulinotropic meglitinide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Renal glucose reabsorption inhibitors to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Personalized pharmacogenomics profiling using whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Network Medicine Strikes a Blow against Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Genetics of type 2 diabetes-pitfalls and possibilities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pharmacogenomics: Current State-of-the-Art

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Variability in the heritability of body mass index: a systematic review and meta-regression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Drug makers and NIH team up to find and validate targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

Zinc transport and diabetes risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.51

31 March 2020

GWAS and drug targets

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27062931

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacological modulation of K(ATP) channels

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27062931

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2016.51

1 reference